Research ArticleHIV

An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals

See allHide authors and affiliations

Science Translational Medicine  11 Sep 2019:
Vol. 11, Issue 509, eaax3447
DOI: 10.1126/scitranslmed.aax3447

Article Information

vol. 11 no. 509

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 15, 2019
  • Accepted for publication August 9, 2019
  • .

Article Versions

Author Information

  1. Michael C. Sneller1,
  2. Katherine E. Clarridge1,
  3. Catherine Seamon2,
  4. Victoria Shi1,
  5. Marek D. Zorawski1,
  6. Jesse Shawn Justement1,
  7. Jana Blazkova1,
  8. Erin D. Huiting1,
  9. Michael A. Proschan3,
  10. Jorge Rodrigo Mora4,
  11. Michael Shetzline4,*,
  12. Susan Moir1,
  13. Henry Clifford Lane1,
  14. Tae-Wook Chun1,, and
  15. Anthony S. Fauci1,
  1. 1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  2. 2Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA.
  3. 3Biostatistics Research Branch, NIAID, NIH, Rockville, MD 20892, USA.
  4. 4Takeda Pharmaceuticals International Co., Cambridge, MA 02139, USA.
  1. Corresponding author. Email: twchun{at}nih.gov
  • * Present address: Ironwood Pharmaceuticals, Cambridge, MA 02142, USA.

  • These authors contributed equally to this work.

Altmetric

Article usage

Article usage: August 2019 to November 2020

AbstractFullPdf
Aug 2019020
Sep 201931061043413
Oct 2019200167108
Nov 20192474650
Dec 20197843649
Jan 20207534930
Feb 20207142434
Mar 20204202627
Apr 20201111930
May 20201312022
Jun 202071246
Jul 2020711913
Aug 2020921811
Sep 2020344624
Oct 2020118141
Nov 202048433

Stay Connected to Science Translational Medicine

Navigate This Article